Comparing the current results to its competitors, Quince Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.36 %, recorded in the same quarter.
Quince Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment characterized by uncertainty in intellectual property protection for proprietary technologies and assets. Competitors may develop and commercialize drug candidates similar or identical to those of the company. Patent positions in the biotechnology and pharmaceutical sectors lack consistent policies regarding claim scope in the United States and internationally. Competitors may have filed or may file patent applications covering similar or competing drug candidates. The company faces risks related to third-party patents that may have priority, as well as potential interference, opposition, or invalidity proceedings. Legal protections may be limited and may not fully safeguard the company's proprietary rights or competitive position. Competitors, some with substantially greater resources and investments in competing technologies, may hold or seek patents that restrict or interfere with the company's ability to manufacture, use, or sell its drug candidates. Additionally, competitors may design around existing claims or develop related or competing technologies that overlap or conflict with the company's patent applications.
March 25, 2025
Unlocking Potential: Quince Therapeutics Fiscal Year 2024 Financial Results and Strategic Developments in Rare Disease Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX), a pioneering biotechnology enterprise headquartered in South San Francisco, is steadfastly advancing the therapeutic landscape for rare diseases by leveraging the intrinsic potential of patient biology. As a distinctive entity in the biotechnology sector, Quince Therapeutics has demonstrated its unwavering commitment to addressing unmet medical needs through innovation and strategic foresight. Today, the company announced a significant update on its developmental pipeline alongside a comprehensive report on its financial performance for...
November 12, 2024
In a significant advancement for the field of pediatric neurology and rare disease therapeutics, Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology firm based in South San Francisco, has presented safety data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; NCT02770807) clinical trial at the 53rd Child Neurology Society (CNS) Annual Meeting. This presentation underscores the company’s dedication to harnessing the power of a patient s own biology to develop innovative treatment options tailored for individuals affected by the rare disorder Ataxia-Telangiectasia (A-T).The data shared at the conference reflects Quince’s commitment to ensuring patient safety and ...
May 13, 2024
Quince Therapeutics, a distinguished player in the biotechnology industry, is persistently pushing the boundaries of innovation with its unique patient-driven drug delivery technology. Its unwavering dedication to revolutionizing the delivery of rare disease therapeutics is the company s unique selling point that sets it apart from its competitors. With the close of the first quarter of 2024, the company reported financial results, exhibiting both its progress and future possibilities.Based in South San Francisco, California, the late-stage biotech entity disclosed an update on its development pipeline while reporting the Q1 2024 financial findings, marking a definite occasion to examine Quince Therapeutics ...
Black Diamond Therapeutics Inc's business model is centered around developing targeted therapies for cancer patients by leveraging its proprietary platform and expertise in precision medicine.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Inmune Bio Inc is a biotechnology company that focuses on developing innovative therapies for treating cancer and neurodegenerative diseases. Their business model revolves around conducting research and clinical trials to develop novel drug candidates targeting specific proteins involved in immune regulation and inflammation. They aim to license or partner their drug candidates with pharmaceutical companies for further development and commercialization, potentially generating revenue through licensing agreements or royalties.
Ionis Pharmaceuticals Inc is a biopharmaceutical company that operates on a two-fold business model. Firstly, the company focuses on discovering and developing antisense drugs, utilizing a unique RNA-targeted technology. Secondly, Ionis collaborates with established pharmaceutical partners to license and commercialize their drugs, allowing for maximum reach and potential commercial success.
Sources:
Quince Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Quince Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
